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Heparin therapy in anti-basement membrane nephritis. The effect
of heparin on the development and progression of a form of an-
tiglomerular basement membrane nephritis was examined in the
rat. Animals which received heparin before and throughout the
period of immunological insult developed lesions which were as
severe, and perhaps more severe, than rats which did not receive
heparin. Inulin clearances were lower in heparin-treated animals
than in untreated rats. Animals in both groups exhibited renal
fibrin-fibrinogen deposition and had increased rates of urinary
fibrin-fibrinogen related antigen excretion. These results indicate
that heparin per se has no beneficial effect on the development of
this form of glomerulonephritis in this species.
Traitment par I'héparine de Ia néphrite par anticorps anti-
membrane basale glomérulaire. L'effect de l'héparine sur Ic develop-
pement et l'évolution d'une variété de néphrite par anticorps anti-
membrane basale glomCrulaire a Cté étudié chez Ic rat. Les
animaux qui reçoivent de l'héparine avant et pendant Ia pCriode d'
agression immunologique développent des lesions qui sont sévCres,
et probablement plus sévères, que ceux qui ne recoivent pas
d'héparine. Les clearances de l'inuline sont inférieures chez les
animaux traitCs par l'héparine. Les animaux des deux groupes ont
des dépôts rénaux de fibrine-fibrinogene et des debits urinaires ac-
crus d'antigCne en rapport avec Ia fibrine et le fibrinogene. Ces
résultats montrent que l'héparine par elle-même n'a pas d'effet
bénefique sur Ic développement de cette variété de glomérulo-
néphrite dans cette espèce.
In 1964, Vassalli and McCluskey suggested that in-
traglomerular coagulation might play a critical rolein the pathogenesis of certain forms of
glomerulonephritis. They demonstrated that a
proliferative lesion could be produced in rabbits by
the induction of glomerular coagulation with throm-
bogenic agents [1], and also showed that the severity
of antiglomerular basement membrane (anti-GBM)
nephritis in rabbits was reduced by anticoagulation
treatment [2]. Both anticoagulation with heparin and
defibrination have a protective effect on the evolution
of rabbit anti-GBM nephritis [3, 4]. However, the
results of treatment with anticoagulant drugs in other
experimental models of glomerulonephritis and in
other species have been equivocal [5, 6]. Fibrin and
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other derivatives of fibrinogen have been
demonstrated within the glomeruli in human
proliferative glomerulonephritis. In addition, there
are increased concentrations of fibrin degradation
products in the serum and urine of patients with
proliferative lesions which are closely related to the
activity of the lesion and the degree of in-
traglomerular fibrin deposition. [7—9]. The possible
role of the coagulation process in the pathogenesis of
human glomerulonephritis has led to a number of
trials with anticoagulant drugs in the treatment of
patients with progressive lesions [10—13]. Although
favorable results have been ascribed to anticoagula-
tion therapy, such patients have often received other
forms of therapy in conjunction with anticoagulants.
Hence, the precise contribution of anticoagulants per
se in these patients is unclear. Moreover, a recent
review of European experience failed to show benefit
from the use of heparin in patients with rapidly
progressive proliferative glomerulonephritis [14]. In
the present study, we have examined the role of
glomerular coagulation in the pathogenesis of anti-
GBM nephritis in the rat and have assessed the effect
of treatment with heparin on the development and
progression of the lesion.
Methods
Glomerulonephritis was induced in 59 Sprague-
Dawley rats weighing 180 to 200 g, using a method
which involves the serial administration of
heterologous antiserum in two stages [15]. In the first
stage, the animals receive a series of three i.v. injec-
tions of goat anti-rat kidney serum. Ten to 12 days
later, the rats receive an injection of rabbit anti-goat
gamma globulin serum and this is repeated four to six
days later. The latter injections constitute the
"autologous" phase of induction of this anti-base-
ment membrane nephritis and produce a severe lesion
in most animals. Four groups of animals were studied
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in parallel. Rats in all groups were given antisera
from the same batch and on the same days. The first
group contained 24 rats which received the antisera
but were not treated. The second group of six rats
received heparin in a dosage of 100 U subcutaneously
every 12 hr. A third group of 23 rats received 200 U
of heparin subcutaneously every 12 hr, and a fourth
group of six rats received 400 U of heparins sub-
cutaneously every 12 hr. The heparin used was from
porcine intestinal mucosa (Liquaemin, Organon,
West Orange, NJ). Heparin injections in the treated
groups were begun 24 hr before the first injection of
antiserum and were continued throughout the study.
All animals were placed in metabolic cages at weekly
intervals and 24-hr collections of urine were obtained
for measurement of protein excretion and fibrin-
fibrinogen related antigen (FRA) excretion. Two to
three weeks after the last antiserum injection, the rats
were lightly anesthetized with ether and polyethylene
cannulae were inserted into the jugular vein and
femoral artery for infusion and blood collection,
respectively. A silastic catheter was inserted into the
bladder for the collection of urine under mineral oil.
The animals were then mounted in restraining
holders and allowed to recover from the anesthesia.
Clearance measurements were begun no sooner than
two hours after the rats had regained consciousness.
Blood for urea nitrogen and plasma sodium, potas-
sium, protein and albumin concentrations was taken
before the priming solutions were given. A priming
dose of inulin was dissolved in 1 ml of 0.9% saline and
inulin and para-aminohippurate (PAH) were infused
in 0.9% saline at a constant rate of 0.05 mI/mm using
a Harvard infusion pump. After a one-hour
equilibration period, three timed urine collections of
approximately 20 mm each were obtained along with
midpoint blood samples.
After completion of the clearance measurements,
the rats were again lightly anesthetized with ether and
a specimen was taken by open biopsy from the left
kidney. One piece of tissue was fixed in 10% formalin
for light microscopic examination. Another piece was
placed in ice-cold saline, transferred to 10% gelatin
and snap-frozen in liquid nitrogen. This was stored at
—20° C until sections 2t thick were cut in a cryostat
and stained with rabbit anti-rat fibrinogen which had
been labelled with fluoresceine isothiocyanate [16].
lnulin concentrations in plasma and urine were
measured by the method of Fuhr, Kaczmarczyk and
Kruttgen [17] and PAH concentrations by the
method of Smith et al [18]. Sodium and potassium
were measured using a flame photometer (IL Model
143). Protein concentrations in urine and plasma
were measured by the method of Lowry et al [19] and
albumin was measured by the method of Ness,
Dickerson and Pastewka [20]. FRA concentration in
urine and serum was measured by the tanned, sen-
sitized red blood cell hemagglutination inhibition im-
munoassay of Merskey et al using rat erythrocytes
[21]. A sensitivity of 0.5 to 1 g/ml was regularly ob-
tained. Anti-rat fibrinogen antiserum, which reacts
with both fibrin and fibrinogen, was obtained from
Cappel Laboratories, Inc., Downington, Penn-
sylvania and was absorbed with rat serum before use.
The fibrinogen concentration of rat plasma, which
was used as a standard in the FRA assay, was
measured by the method of Ratnoff and Menzie [22].
Whole blood clotting time was measured by a capil-
lary tube technique [23].
Morphologic assessment was made by a
pathologist without knowledge of either the func-
tional characteristics or treatment regimen. Light
microscopic grading of hematoxylin-eosin stained
sections cut at 4z was as follows: grade 0, no abnor-
mality; grade 1, slight basement membrane thicken-
ing and mild mesangial hypercellularity of the
glomerular tuft; grade 2, marked mesangial I ypercel-
lularity of the glomerular tuft without c escents;
grade 3, collapse of capillary loops, marked
mesangial hypercellularity and epithelial cre ,cents in
some glomeruli; grade 4, collapse of capilla y loops,
marked mesangial hypercellularity and pithelial
crescents in most glomeruli.
The intensity of immunofluorescent staining for
fibrin-fibrinogen was arbitrarily graded from 0 to 3+.
The latter indicates marked fluorescence in most
glomeruli. Student's t test was used to assess the
significance of differences between treated and un-
treated groups.
Results
The effect of heparin on whole blood clotting time
is shown in Table 1. Rats receiving 100 U of heparin
Table 1. Bleeding indexesa
Hematocrit
.
Heparin
dosage
Clotting
mm
time
Group % U/12 hr 6 hr l2hr
Untreated 43.3 + 1.5 nil 2—3 2—3
(N = 24)
Heparin 100 44.2 + 1.8 100 2—3 2—3
(N =6)
Heparin 200 40.7 1.7 200 20—30 4—6
(N= 19)
Heparin400 28.3+3.5 400 120 20—30
(N =6)
a Values are means + SCM.
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at 12 hourly intervals had normal clotting times.
However, the activity of a plasma inhibitor of ac-
tivated factor X was increased by an average of 25%
even at this low dosage [24]. Clotting time increased
several fold in rats given either 200 or 400 U of
heparin. These dosages prolonged clotting time
throughout the 12 hr between injections. Bleeding ap-
peared to be a problem only in rats which received
400 U of heparin every 12 hr. Several of these
animals developed subcutaneous hematomata at in-
jection sites during the first week of treatment with
heparin. The mean hematocrit value in this group of
rats at the time of clearance studies was 28.3% com-
pared with over 40% in all other groups.
Morphologic changes. Fig. 1, a through d, il-
lustrates, the spectrum of light microscopic changes
observed in this study. The glomeruli in Fig. la and b
were obtained from two animals with normal and
moderately reduced filtration rates, respectively.
They demonstrate mild hypercellularity and some
basement membrane thickening. Fig. ic and d shows
representative sections from two rats with advanced
renal insufficiency. Such animals have extensive cres-
cent formation and intraglomerular fibrin deposition.
The glomerulus in Fig. id is severely damaged and
casts are present in some tubules. Fig. 2 shows the
distribution of fibrin in two glomeruli from a rat with
severe disease. The fibrin is prominent in epithelial
crescents and is also present in Bowman's space. Rats
with the most severely damaged glomeruli showed
the most intense immunofluorescence for fibrin-
fibrinogen.
A large proportion of both heparin-treated and un-
treated animals developed severe lesions. Fifty-seven
percent of untreated rats had epithelial crescents in
most glomeruli and 52% exhibited intense im-
munofluorescence. A somewhat higher proportion
(71%) of rats given 200 U of heparin every 12 hr
had grade 4 light microscopic changes and 63% had
grade 3 immunofluorescence for fibrin-fibrinogen.
Epithelial crescents were present in 17 of the 19 rats
in this group, and fibrin deposition was demonstrable
in all but one. All rats receiving 400 U of heparin
twice daily had severe lesions with abundant fibrin
deposition. Thus, the glomerular lesion appeared to
be more uniformly severe in rats receiving heparin at
these dosages, and fibrin deposition was prominent in
such animals.
Functional changes. Table 2 summarizes the results
of clearance measurements and urinary protein and
FRA excretion in the four groups of rats. The
average inulin clearance of 1.04 0.18 mI/mm in un-
treated rats represents a reduction from normal of
approximately 50%. Individual clearance values in
this group ranged from 0.1 to 3.1 ml/min. PAH
clearances were also reduced and filtration fraction
averaged 22%. Animals receiving heparin in the
lowest dosage had values for inulin and PAH
clearances which were similar to those found in un-
treated animals. However, rats given heparin at the
higher dosages exhibited a more marked reduction in
inulin and PAH clearances than rats in the untreated
group. The highest value for inulin clearance in the
group of animals given 200 U of heparin twice daily
was 1.2 mI/mm. The mean values for both inulin
clearance and PAH clearance were significantly lower
than in the untreated rats. The animals which
received 400 U of heparin at 12-hr intervals had mean
inulin and PAH clearance values of 0.36 0.08 and
1.69 + 0.51 mI/mm, respectively. The highest value
for inulin clearance in this group was 0.7 ml/min.
Plasma albumin concentration was significantly
lower in rats given either 200 or 400 U of heparin
every 12 hr than in untreated rats. Urinary protein
excretion averaged 432 22.5 and 427 69.7 mg/24
hr in the 200- and 400-U heparin groups, respectively.
Animals which received no heparin excreted an
average of 391 35.9 mg/24 hr. The 24-hr FRA ex-
cretion was significantly higher in rats in the 200- and
400-U heparin groups than in the untreated animals,
which also exhibited increased FRA excretion.
Figs. 3 and 4 compare the rates of protein and
FRA excretion in rats given 200 U of heparin every
12 hr with excretion rates in untreated animals. A
progressive rise in the urinary excretion of both
protein and FRA occurred in both groups during the
three weeks after the administration of rabbit anti-
goat antiserum. In some animals, urinary FRA ex-
cretion rose from less than 50 to over 10,000 !zg/24
hr, and rats receiving sufficient heparin to prolong
their clotting time over this interval had higher rates
of FRA excretion than untreated animals. There ap-
peared to be a direct relationship between the rate of
ERA excretion and the degree of fibrin deposition in
glomeruli in both untreated and heparin-treated rats
(Fig. 5).
The relationship between urinary FRA excretion
and inulin clearance is depicted in Fig. 6. Rats with
the most severe lesions had higher rates of FRA ex-
cretion than rats which developed little or no reduc-
tion in inulin clearance. This relationship held in
heparinized rats as well as in animals which received
no treatment. The highest values for FRA excretion
and the lowest values for inulin clearance were pres-
ent in those rats which had received heparin at the
higher dosage levels.
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Fig. 1. Glomeruli from four rats with lesions of varying severity: a, grade 1,' b, grade 2; c, grade 3; d, grade 4 (hematoxylin-eosin, X350).
Discussion several lines of evidence appear to incriminate the
coagulation system in the evolution of the more
immunological reactions appear to play a central destructive forms of this lesion. The induction of in-
role in the pathogenesis and progression of many travascular coagulation in the rabbit has been shown
types of glomerulonephritis [25, 26]. In addition, to result in a glomerulitis with proliferation of
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mesangial cells and a histological picture similar to
that seen in immunologically induced forms of
glomerulonephritis [1]. Fibrin deposits in capillaries
and Bowman's space constitute a prominent feature
of rabbit anti-basement membrane nephritis [2], NZB
mouse nephritis [27] and Aleutian mink nephritis
[28]. In human disease, intraglomerular fibrin has
been noted in poststreptococcal and rapidly progres-
sive glomerulonephritis, as well as in systemic lupus
erythematosus and Goodpasture's disease [29, 30].
Fibrin degradation products have been demonstrated
in the serum and urine of such patients, and have
been related both to the activity of the disease process
and to the extent of glomerular fibrin deposition
[7—9]. It has also been suggested that antithrombotic
agents interfere with the evolution of both ex-
perimental and human glomerulonephritis [2—4, 12].
However, fibrin deposition is not a major feature of
experimental immune complex nephritis [31], and at-
tempts to modify the coagulation system in order to
prevent or ameliorate glomerulonephritis in ex-
Fig. 2. Fibrin-fibrinogen deposition in
glomeruli.
perimental animals have not been uniformly success-
ful [5, 6]. The precise role of anticoagulation therapy
in the clinical treatment of glomerulonephritis has
also been difficult to assess. Some patients appear to
improve when anticoagulation therapy is used in con-
junction with immunosuppressive therapy [10—12];
others do not [13, 14]. Moreover, the simultaneous
administration of a variety of agents with vastly
different pharmacologic effects makes it difficult to
assess the specific contribution of each drug.
In the present study, heparin administration at
three dosage levels had no beneficial effect on the an-
ti-basement membrane glomerulonephritis model
employed. The lesion was characterized by basement
membrane thickening, epithelial cell proliferation
with crescent formation and progression to
glomerular obliteration. Fibrinogen derivatives were
found in crescents and Bowman's space, and urinary
FRA excretion was elevated. The degree of fibrin
deposition and the rate of FRA excretion were
closely related to both the severity of the histological
Table 2. Clearance data and urinary protem and FRA excretiona
Group
Weight
g
BUN
mi/loom!
Plasma
albumin
g/lOOm!
C
mi/mm
CPAH
mi/mm
Urinary
protein
mg/24hr
Urinary
FRA
itg/24 hr
Untreated 233 + 4.3 66.9 9.1 2.38 + 0.26 1.04 0.18 5.40 + 0.70 391 35.1 1050
Heparin, 100 U 238 12.4 99.6 + 37.4 2.57 0.57 1.12 0.39 5.42 1.59 317 + 92.0 720
Heparin, 200 U 220 3.5 62.6 6.7 1.65 015b 0.52 0.08h 3.11 + 0.5P' 432 + 22.5 4540c
Heparin, 400 U 222 8.2 189 25.5 1.16 0.24c 0.36 0.08 1.69 0.5lc 427 69.7 4570d
avalues arc means SEM.
bDifferent from untreated group at P < 0.02
eDifferent from untreated group at P < 0.005.
dDifferent from untreated group at P < 0.05.
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Fig. 3. Urinary protein excretion in untreated rats (S). and in rats
given 200 U of heparin every 12 hr (0). Values are means
lesion and the degree of functional impairment. Rats
receiving heparin at dosages sufficient to produce
systemic anticoagulation developed lesions that were
as severe and perhaps more severe than lesions in un-
treated animals.
The action of heparin could, in theory, lead to
either amelioration or worsening of immunologically
induced glomerular damage. Heparin has an an-
tithrombin effect and inhibits thrombin-induced
platelet aggregation. Smaller dosages enhance the ac-
tivity of a naturally occurring inhibitor of activated
factor X, thereby interfering with the coagulation
process [24]. If intraglomerular clotting promotes in-
flammation and cellular proliferation, anticoagula-
tion could be beneficial. On the other hand, in-
Intensity of immunofluorescence
for fibrin/fibrinogen
Fig. 5. Urinary ERA excretion and intensity of i,nmunofluorescence
for fibrin-fibrinogen in glomeruli of untreated rats and rats given
heparin. Untreated (•); heparin, 100 U (A); heparin, 200 U (0);
heparin, 400 U(Liil).
terference with coagulation could theoretically result
in a more severe lesion. If severely damaged
glomerular capillaries are obliterated by thrombi, the
residual capillaries in the same glomerulus could con-
tinue to contribute to filtration. However, if severely
damaged glomerular capillaries are not occluded,
fibrinogen and other plasma constituents could pass
across the damaged area into Bowman's space.
Fibrin deposition in Bowman's space has been
thought to promote crescent formation, which in turn
may lead to eventual obliteration of the entire
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glomerulus [32]. Focal disruption of the glomerular
basement membrane with abundant crescent forma-
tion has been observed in patients with rapidly
progressive glomerulonephritis [33-35]. Fibrinous
plugging of the discontinuities in the glomerular
basement membrane, as well as occlusion of damaged
capillaries, has also been shown [35]. It is possible
that interference with the formation of fibrin in this
setting could prolong the leakage of plasma and
formed blood elements into Bowman's space and
result in an even more severe lesion. Hoyer, Michael
and Hoyer have shown that crescents in patients with
rapidly progressive glomerulonephritis contain fibrin
but not antihemophitic globulin [36]. Thus, the for-
mation of fibrin in Bowman's space may not be
dependent entirely upon the conventional intrinsic or
extrinsic clotting pathways, and heparin might not be
effective at this local level. The foregoing observa-
tions could provide an explanation both for our find-
ings and for the equivocal results of herapin therapy
in patients with glomerulonephritis. It must be
stressed however, that our observations were made
using an experimental model of anti-basement mem-
brane glomerulonephritis in the rat, which may differ
in many essential ways from other experimental
models in other species and from human glomerulo-
nephritis. It is also possible that heparin, given in
dosages larger than those required to prolong clot-
ting, might have a protective effect. The combined
use of heparin with agents which inhibit platelet
aggregation or which have anti-inflammatory effects
could also produce an entirely different result.
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